HRP20170023T1 - Kristalni oblik pemirolasta - Google Patents
Kristalni oblik pemirolasta Download PDFInfo
- Publication number
- HRP20170023T1 HRP20170023T1 HRP20170023TT HRP20170023T HRP20170023T1 HR P20170023 T1 HRP20170023 T1 HR P20170023T1 HR P20170023T T HRP20170023T T HR P20170023TT HR P20170023 T HRP20170023 T HR P20170023T HR P20170023 T1 HRP20170023 T1 HR P20170023T1
- Authority
- HR
- Croatia
- Prior art keywords
- sodium
- pemirolast
- compound according
- solvent
- crystallization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Secondary Cells (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18734809P | 2009-06-16 | 2009-06-16 | |
| US18735509P | 2009-06-16 | 2009-06-16 | |
| EP10732402.2A EP2443120B1 (en) | 2009-06-16 | 2010-06-15 | Crystalline form of pemirolast |
| PCT/GB2010/001168 WO2010146348A2 (en) | 2009-06-16 | 2010-06-15 | New crystalline form of pemirolast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170023T1 true HRP20170023T1 (hr) | 2017-03-10 |
Family
ID=43264726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170023TT HRP20170023T1 (hr) | 2009-06-16 | 2010-06-15 | Kristalni oblik pemirolasta |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20120157415A1 (OSRAM) |
| EP (2) | EP3141549A1 (OSRAM) |
| JP (2) | JP5722317B2 (OSRAM) |
| KR (2) | KR20170049645A (OSRAM) |
| CN (1) | CN102596202B (OSRAM) |
| AR (1) | AR077915A1 (OSRAM) |
| AU (1) | AU2010261540B2 (OSRAM) |
| BR (1) | BRPI1015559A2 (OSRAM) |
| CA (1) | CA2765408A1 (OSRAM) |
| CY (1) | CY1118413T1 (OSRAM) |
| DK (1) | DK2443120T3 (OSRAM) |
| EA (1) | EA025865B1 (OSRAM) |
| ES (1) | ES2613059T3 (OSRAM) |
| HR (1) | HRP20170023T1 (OSRAM) |
| HU (1) | HUE032978T2 (OSRAM) |
| IL (1) | IL216670A (OSRAM) |
| LT (1) | LT2443120T (OSRAM) |
| ME (1) | ME02685B (OSRAM) |
| MX (1) | MX2011013676A (OSRAM) |
| NZ (1) | NZ596747A (OSRAM) |
| PL (1) | PL2443120T3 (OSRAM) |
| PT (1) | PT2443120T (OSRAM) |
| RS (1) | RS55558B1 (OSRAM) |
| SA (1) | SA114350792B1 (OSRAM) |
| SG (1) | SG176295A1 (OSRAM) |
| SI (1) | SI2443120T1 (OSRAM) |
| SM (2) | SMT201700085T1 (OSRAM) |
| TW (1) | TWI504599B (OSRAM) |
| UY (1) | UY32711A (OSRAM) |
| WO (2) | WO2010146348A2 (OSRAM) |
| ZA (1) | ZA201109045B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013510837A (ja) * | 2009-11-13 | 2013-03-28 | カルドズ・アーベー | 全身性軽度炎症の新しい処置 |
| AU2013381855B2 (en) * | 2013-03-09 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20160243122A1 (en) | 2014-10-23 | 2016-08-25 | Rspr Pharma Ab | Use of pemirolast in the treatment of acute asthma |
| WO2016102941A1 (en) | 2014-12-22 | 2016-06-30 | Rspr Pharma Ab | New combination of pemirolast and montelukast |
| GB201518831D0 (en) | 2015-10-23 | 2015-12-09 | Rspr Pharma Ab | New use |
| JP6596697B2 (ja) * | 2016-10-03 | 2019-10-30 | ブリベンションファーマシューティカル（シャンハイ）インコーポレイテッド | Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JP2504788B2 (ja) | 1987-11-10 | 1996-06-05 | 東京田辺製薬株式会社 | ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤 |
| JP2837449B2 (ja) * | 1989-08-11 | 1998-12-16 | 東京田辺製薬株式会社 | ピリド［１，２―ａ］ピリミジン誘導体の製造法 |
| ITMI20011764A1 (it) | 2001-08-10 | 2003-02-10 | Dinamite Dipharma Spa | Metodo per l'ottenimento del pemirolast ad elevata purezza |
| US8686189B2 (en) | 2005-09-16 | 2014-04-01 | Daiichi Sankyo Company, Limited | Optically active diamine derivative and process for producing the same |
| ES2394984T3 (es) | 2006-12-18 | 2013-02-07 | Cardoz Ab | Nueva combinación para uso en el tratamiento de trastornos inflamatorios |
| AU2007336077A1 (en) | 2006-12-20 | 2008-06-26 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
-
2010
- 2010-06-15 PT PT107324022T patent/PT2443120T/pt unknown
- 2010-06-15 ES ES10732402.2T patent/ES2613059T3/es active Active
- 2010-06-15 PL PL10732402T patent/PL2443120T3/pl unknown
- 2010-06-15 DK DK10732402.2T patent/DK2443120T3/en active
- 2010-06-15 SG SG2011088655A patent/SG176295A1/en unknown
- 2010-06-15 WO PCT/GB2010/001168 patent/WO2010146348A2/en not_active Ceased
- 2010-06-15 US US13/378,787 patent/US20120157415A1/en not_active Abandoned
- 2010-06-15 NZ NZ596747A patent/NZ596747A/en not_active IP Right Cessation
- 2010-06-15 CA CA2765408A patent/CA2765408A1/en not_active Abandoned
- 2010-06-15 TW TW099119396A patent/TWI504599B/zh not_active IP Right Cessation
- 2010-06-15 ME MEP-2017-8A patent/ME02685B/me unknown
- 2010-06-15 HR HRP20170023TT patent/HRP20170023T1/hr unknown
- 2010-06-15 EP EP16194237.0A patent/EP3141549A1/en not_active Withdrawn
- 2010-06-15 WO PCT/GB2010/001159 patent/WO2010146341A2/en not_active Ceased
- 2010-06-15 SI SI201031380A patent/SI2443120T1/sl unknown
- 2010-06-15 EA EA201200017A patent/EA025865B1/ru not_active IP Right Cessation
- 2010-06-15 RS RS20170003A patent/RS55558B1/sr unknown
- 2010-06-15 UY UY0001032711A patent/UY32711A/es not_active Application Discontinuation
- 2010-06-15 BR BRPI1015559A patent/BRPI1015559A2/pt not_active IP Right Cessation
- 2010-06-15 HU HUE10732402A patent/HUE032978T2/hu unknown
- 2010-06-15 SM SM20170085T patent/SMT201700085T1/it unknown
- 2010-06-15 KR KR1020177012036A patent/KR20170049645A/ko not_active Ceased
- 2010-06-15 LT LTEP10732402.2T patent/LT2443120T/lt unknown
- 2010-06-15 AU AU2010261540A patent/AU2010261540B2/en not_active Ceased
- 2010-06-15 EP EP10732402.2A patent/EP2443120B1/en active Active
- 2010-06-15 JP JP2012515552A patent/JP5722317B2/ja not_active Expired - Fee Related
- 2010-06-15 MX MX2011013676A patent/MX2011013676A/es active IP Right Grant
- 2010-06-15 KR KR1020127001227A patent/KR20120032530A/ko not_active Ceased
- 2010-06-15 CN CN201080026883.3A patent/CN102596202B/zh not_active Expired - Fee Related
- 2010-06-16 AR ARP100102136A patent/AR077915A1/es unknown
- 2010-06-16 SA SA114350792A patent/SA114350792B1/ar unknown
-
2011
- 2011-11-29 IL IL216670A patent/IL216670A/en not_active IP Right Cessation
- 2011-12-08 ZA ZA2011/09045A patent/ZA201109045B/en unknown
-
2014
- 2014-05-12 US US14/274,951 patent/US9006431B2/en not_active Expired - Fee Related
-
2015
- 2015-03-24 JP JP2015060587A patent/JP2015120750A/ja active Pending
-
2016
- 2016-12-28 US US15/392,497 patent/US20170202839A1/en not_active Abandoned
-
2017
- 2017-01-11 CY CY20171100039T patent/CY1118413T1/el unknown
- 2017-02-08 SM SM201700085T patent/SMT201700085B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011126894A5 (OSRAM) | ||
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| HRP20180970T1 (hr) | Policiklični lpa1 antagonist i njegove primjene | |
| HRP20201198T1 (hr) | Kristalni 2-fluor-3-nitrotoluen i postupak njegove priprave | |
| HRP20220665T1 (hr) | Natrijeve soli 5-brom-2-(alfa-hidroksipentil)benzojeve kiseline u različitim kristalnim oblicima i postupak njihove pripreme | |
| ME02655B (me) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| HRP20130950T1 (hr) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina | |
| RU2015145732A (ru) | Способ получения гидроксида 1-адамантилтриметиламмония | |
| HRP20200922T1 (hr) | Postupak za proizvodnju kristalnog oblika modifikacije a kalkobutrola | |
| JP2016513060A5 (OSRAM) | ||
| RU2013137753A (ru) | Твердые формы ингибитора гиразы (r)-1-этил-3-[5-[2-(1-гидрокси-1-метилэтил)пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил]мочевины | |
| BR112014001505A2 (pt) | formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2- (1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida | |
| JP2012530118A5 (OSRAM) | ||
| BR112014001530A2 (pt) | formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzeno sulfonamida | |
| CN102515593A (zh) | 一种利用盐溶液生产半水石膏的方法 | |
| MD20120130A2 (en) | Delta crystalline form of the L-arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it | |
| NZ700221A (en) | Ralfinamide methanesulfonate salts | |
| ES2523346T3 (es) | Un proceso para preparar sal de tricloroaminoplatinato y los productos obtenidos en el mismo | |
| HRP20211524T1 (hr) | Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju | |
| CN103910659A (zh) | 2-硝基-4-甲磺酰基苯甲酸的精制方法及其中间体 | |
| RU2019115782A (ru) | Аморфный тринатрий сакубитрил вальсартан и способ его получения | |
| HRP20161186T1 (hr) | Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama | |
| RU2014112315A (ru) | Кристаллическая форма бромида тиотропия | |
| JP2015524456A5 (OSRAM) | ||
| CL2012001528A1 (es) | Proceso para preparar la forma cristalina a de ilaprazol a partir de una sal inorganica de ilaprazol y posterior neutralizacion de la sal con un acido en un solvente de reaccion; y proceso para preparar la forma cristalina b de ilaprazol en la forma cristalina a de ilaprazol. |